Protoplasmic astrocytoma: Difference between revisions
Jump to navigation
Jump to search
| Line 182: | Line 182: | ||
*** It doesn't affect survival since it cannot prevent transformation of [[low grade astrocytoma]] to [[high grade astrocytoma]]. | *** It doesn't affect survival since it cannot prevent transformation of [[low grade astrocytoma]] to [[high grade astrocytoma]]. | ||
***Preferred regimen: 50 t0 54 Gy | ***Preferred regimen: 50 t0 54 Gy | ||
**1.3 Adjunctive [[chemotherapy]] | **1.3 Adjunctive [[chemotherapy]]<ref name="pmid27050206">{{cite journal |vauthors=Buckner JC, Shaw EG, Pugh SL, Chakravarti A, Gilbert MR, Barger GR, Coons S, Ricci P, Bullard D, Brown PD, Stelzer K, Brachman D, Suh JH, Schultz CJ, Bahary JP, Fisher BJ, Kim H, Murtha AD, Bell EH, Won M, Mehta MP, Curran WJ |title=Radiation plus Procarbazine, CCNU, and Vincristine in Low-Grade Glioma |journal=N. Engl. J. Med. |volume=374 |issue=14 |pages=1344–55 |date=April 2016 |pmid=27050206 |pmc=5170873 |doi=10.1056/NEJMoa1500925 |url=}}</ref><ref name="pmid22851558">{{cite journal |vauthors=Shaw EG, Wang M, Coons SW, Brachman DG, Buckner JC, Stelzer KJ, Barger GR, Brown PD, Gilbert MR, Mehta MP |title=Randomized trial of radiation therapy plus procarbazine, lomustine, and vincristine chemotherapy for supratentorial adult low-grade glioma: initial results of RTOG 9802 |journal=J. Clin. Oncol. |volume=30 |issue=25 |pages=3065–70 |date=September 2012 |pmid=22851558 |pmc=3732006 |doi=10.1200/JCO.2011.35.8598 |url=}}</ref> | ||
***1.3.1 [[Temozolomide]] | ***1.3.1 [[Temozolomide]] | ||
***1.3.2 PVC ([[Procarbazine]], [[Lomustine]], [[Vincristine]]) | ***1.3.2 PVC ([[Procarbazine]], [[Lomustine]], [[Vincristine]]) | ||
Latest revision as of 22:11, 27 July 2019
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Sujit Routray, M.D. [2]Roukoz A. Karam, M.D.[3]
Synonyms and keywords: Protoplasmic astrocytomas; Diffuse astrocytoma; Low grade astrocytoma
Overview
Protoplasmic astrocytoma is a rare variant of diffuse low grade astrocytoma with characteristic histological and imaging features. It has been suggested that protoplasmic astrocytoma represents a variant of dysembryoplastic neuroepithelial tumors (DNET), as they share histologic and imaging features. Currently, protoplasmic astrocytoma is classified as a subtype of diffuse low-grade astrocytoma. The possibility that a primary cerebral neoplasm represents a protoplasmic astrocytoma should be considered in a patient with a large frontal or temporal tumor that has a very high signal on T2 with a large proportion of the tumor showing substantial T2 FLAIR suppression.
Classification
Protoplasmic astrocytoma is a subtype of astrocytoma and is included in the classification of astrocytoma. For more information about the classification of astrocytoma, click here.
Pathophysiology
Gross Pathology
- Protoplasmic astrocytoma appear to have a predilection for the frontal and temporal lobes.
Microscopic Pathology
- On microscopic histopathological analysis, protoplasmic astrocytoma is characterized by:[1]
- Scant cytoplasm
- Rounded prominent nuclear contour
- Flaccid processes
- Low cellular density
- Mild nuclear atypia (enlarged, irregular contour, hyperchromasia, and coarsened nuclear chromatin pattern)
- Mucinous fluid containing microcystic spaces (prominent feature)
- Abscence of mitoses, microvascular proliferation, and necrosis
- temporal and frontal lobes were the most likely site of origin.
Immunohistochemistry
- Protoplasmic astrocytoma is demonstrated by positivity to tumor marker such as GFAP.
Causes
There are no causes for protoplasmic astrocytoma.
Differentiating Protoplasmic Astrocytoma from other Diseases
- Protoplasmic astrocytoma must be differentiated from:
Epidemiology and Demographics
Age
- Protoplasmic astrocytoma is a rare disease that tends to affect young adults.
- The mean age at diagnosis is 32 years.
Gender
- Males are more commonly affected with protoplasmic astrocytoma than females. The male to female ratio is approximately 1.67 to 1.[1]
Risk Factors
There are no established risk factors for protoplasmic astrocytoma.
Screening
There is insufficient evidence to recommend routine screening for protoplasmic astrocytoma.
Natural History, Complications and Prognosis
Natural History
- If left untreated, patients with protoplasmic astrocytoma may progress to develop seizures, focal neurological deficits, and hydrocephalus.[2]
- Protoplasmic astrocytoma is a slow growing tumor with an indolent course.
Complications
- Common complication of protoplasmic astrocytoma include:[2]
Diagnosis
Diagnostic Study of Choice
The diagnosis of protoplasmic astrocytoma is based on a tissue biopsy.
History and Symptoms
- When evaluating a patient for protoplasmic astrocytoma, you should take a detailed history of the presenting symptom (onset, duration, and progression), other associated symptoms, and a thorough family and past medical history review.
- Symptoms of protoplasmic astrocytoma include:[2]
Physical Examination
Patients with protoplasmic astrocytoma usually appear
Laboratory Findings
There are no diagnostic laboratory findings associated with protoplasmic astrocytoma.
Electrocardiogram
There are no ECG findings associated with protoplasmic astrocytoma.
X-ray
There are no x-ray findings associated with protoplasmic astrocytoma.
Echocardiography or Ultrasound
There are no echocardiography/ultrasound findings associated with protoplasmic astrocytoma.
CT scan
- Head CT scan is helpful in the diagnosis of protoplasmic astrocytoma. On CT scan, protoplasmic astrocytoma is characterized by:[3]
- Hypodense mass
- Positive mass effect
- No enhancement
- Cystic or fluid attenuation, due to the aforementioned prominent mucinous microcystic component
MRI
- The possibility that a primary cerebral neoplasm represents a protoplasmic astrocytoma should be considered in a patient with a large frontal or temporal tumor that has a very high signal on T2 with a large proportion of the tumor showing substantial T2 FLAIR suppression.[4]
- Brain MRI is helpful in the diagnosis of protoplasmic astrocytoma. On MRI, protoplasmic astrocytoma is characterized by:[3][5]
| MRI component | Findings |
|---|---|
|
T1 |
|
|
T2 |
|
|
Fluid-attenuated inversion recovery (FLAIR) |
|
|
T1 with contrast |
|
|
Diffusion weighted imaging (DWI) |
|
Other Imaging Findings
Magnetic Resonance Spectroscopy
- MR spectroscopy may be helpful in the diagnosis of protoplasmic astrocytoma, which demonstrates elevated choline/creatine ratio.[3]
Magnetic Resonance Perfusion
- MR perfusion may be helpful in the diagnosis of protoplasmic astrocytoma, which demonstrates no elevation of relative cerebral blood volume (rCBV).[3]
Other Diagnostic Studies
Electroencephalogram
- Electroencephalogram (EEG) is performed in cases of protoplasmic astrocytoma to record the continuous electrical activity of the brain and locate the seizure activity.[6]
Treatment
Medical Therapy
There is no specific chemotherapy regimen for protoplasmic astrocytoma. It is managed as an astrocytoma.
- Post surgical medical therapy is recommended in all patients with astrocytoma tumor.
Astrocytoma
- 1 Grade 1 and 2 - Low grade astrocytomas
- 1.1 Wait and see[7][8]
- The wait and see approach is for young patient with complete or nearly complete tumor resection.
- since the low grade astrocytoma will finally grow to high grade astrocytoma, we should screen these patients with contrast MRI every 4 month.
- 1.2 Radiation therapy[9][10]
- Immediate post surgery radiation therapy can reduce the progression rate.
- It doesn't affect survival since it cannot prevent transformation of low grade astrocytoma to high grade astrocytoma.
- Preferred regimen: 50 t0 54 Gy
- 1.3 Adjunctive chemotherapy[11][12]
- 1.3.1 Temozolomide
- 1.3.2 PVC (Procarbazine, Lomustine, Vincristine)
- Based on previous studies, patients who get chemotherapy along with radiotherapy immediately after surgery has better outcome.
- 1.1 Wait and see[7][8]
- 2 Grade 3 - Anaplastic astrocytoma
- 2.1 Radiotherapy+ chemotherapy (Temozolomide)[13][14]
- Studies demonstrated that the combination of radiotherapy and chemotherapy with temozolomide is more effective.
- 2.2 Radiation
- 2.3 Chemotherapy
- 2.3.1 Procarbazine, Lomustine, Vincristine
- 2.3.2 Procarbazine, Lomustine, Temozolomide[15][16]
- 2.1 Radiotherapy+ chemotherapy (Temozolomide)[13][14]
- 3 Grade 4 - Glioblastoma multiform
- 3.1 Chemotherapy (± radiotherapy)[17][18]
- 3.1.1 Temozolomide
- 3.2 Bevacizumab[19]
- A monoclonal antibody which bind to VEGF and inactivate it.
- 3.3 Alternating electric fields[20]
- A portable device which will be placed on the scalp for generating TT fields. The combination of this device with Temozolomide will significantly increase survival.
- 3.4 Carmustine polymer wafers[21]
- Implanted at the time of surgery.
- Can be used in combination with chemotherapy or radiation.
- 3.1 Chemotherapy (± radiotherapy)[17][18]
References
- ↑ 1.0 1.1 Prayson RA, Estes ML (1995). "Protoplasmic astrocytoma. A clinicopathologic study of 16 tumors". Am J Clin Pathol. 103 (6): 705–9. doi:10.1093/ajcp/103.6.705. PMID 7785654.
- ↑ 2.0 2.1 2.2 Clinical presentation of protoplasmic astrocytoma. Dr Bruno Di Muzio and A.Prof Frank Gaillard et al. Radiopaedia 2016. http://radiopaedia.org/articles/protoplasmic-astrocytoma. Accessed on January 8, 2016
- ↑ 3.0 3.1 3.2 3.3 Radiological features of protoplasmic astrocytoma. Dr Bruno Di Muzio and A.Prof Frank Gaillard et al. Radiopaedia 2016. http://radiopaedia.org/articles/protoplasmic-astrocytoma. Accessed on January 8, 2016
- ↑ Tay KL, Tsui A, Phal PM, Drummond KJ, Tress BM (2011). "MR imaging characteristics of protoplasmic astrocytomas". Neuroradiology. 53 (6): 405–11. doi:10.1007/s00234-010-0741-2. PMID 20644924.
- ↑ Radiographic features of low grade infiltrative astrocytoma. Dr Ahmed Abd Rabou and A.Prof Frank Gaillard et al. Radiopaedia 2016. http://radiopaedia.org/articles/low-grade-infiltrative-astrocytoma. Accessed on January 8, 2016
- ↑ Radiographic features of fibrillary astrocytoma. Dr Henry Knipe and A.Prof Frank Gaillard et al. Radiopaedia 2016. http://radiopaedia.org/articles/fibrillary-astrocytoma. Accessed on January 4, 2016
- ↑ Ricard D, Kaloshi G, Amiel-Benouaich A, Lejeune J, Marie Y, Mandonnet E, Kujas M, Mokhtari K, Taillibert S, Laigle-Donadey F, Carpentier AF, Omuro A, Capelle L, Duffau H, Cornu P, Guillevin R, Sanson M, Hoang-Xuan K, Delattre JY (May 2007). "Dynamic history of low-grade gliomas before and after temozolomide treatment". Ann. Neurol. 61 (5): 484–90. doi:10.1002/ana.21125. PMID 17469128.
- ↑ Shaw EG, Berkey B, Coons SW, Bullard D, Brachman D, Buckner JC, Stelzer KJ, Barger GR, Brown PD, Gilbert MR, Mehta M (November 2008). "Recurrence following neurosurgeon-determined gross-total resection of adult supratentorial low-grade glioma: results of a prospective clinical trial". J. Neurosurg. 109 (5): 835–41. doi:10.3171/JNS/2008/109/11/0835. PMC 3833272. PMID 18976072.
- ↑ van den Bent MJ, Afra D, de Witte O, Ben Hassel M, Schraub S, Hoang-Xuan K, Malmström PO, Collette L, Piérart M, Mirimanoff R, Karim AB (2005). "Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial". Lancet. 366 (9490): 985–90. doi:10.1016/S0140-6736(05)67070-5. PMID 16168780.
- ↑ Ryken TC, Parney I, Buatti J, Kalkanis SN, Olson JJ (December 2015). "The role of radiotherapy in the management of patients with diffuse low grade glioma: A systematic review and evidence-based clinical practice guideline". J. Neurooncol. 125 (3): 551–83. doi:10.1007/s11060-015-1948-1. PMID 26530266.
- ↑ Buckner JC, Shaw EG, Pugh SL, Chakravarti A, Gilbert MR, Barger GR, Coons S, Ricci P, Bullard D, Brown PD, Stelzer K, Brachman D, Suh JH, Schultz CJ, Bahary JP, Fisher BJ, Kim H, Murtha AD, Bell EH, Won M, Mehta MP, Curran WJ (April 2016). "Radiation plus Procarbazine, CCNU, and Vincristine in Low-Grade Glioma". N. Engl. J. Med. 374 (14): 1344–55. doi:10.1056/NEJMoa1500925. PMC 5170873. PMID 27050206.
- ↑ Shaw EG, Wang M, Coons SW, Brachman DG, Buckner JC, Stelzer KJ, Barger GR, Brown PD, Gilbert MR, Mehta MP (September 2012). "Randomized trial of radiation therapy plus procarbazine, lomustine, and vincristine chemotherapy for supratentorial adult low-grade glioma: initial results of RTOG 9802". J. Clin. Oncol. 30 (25): 3065–70. doi:10.1200/JCO.2011.35.8598. PMC 3732006. PMID 22851558.
- ↑ Juratli TA, Lautenschläger T, Geiger KD, Pinzer T, Krause M, Schackert G, Krex D (September 2015). "Radio-chemotherapy improves survival in IDH-mutant, 1p/19q non-codeleted secondary high-grade astrocytoma patients". J. Neurooncol. 124 (2): 197–205. doi:10.1007/s11060-015-1822-1. PMID 26033545.
- ↑ Shin JY, Diaz AZ (September 2016). "Anaplastic astrocytoma: prognostic factors and survival in 4807 patients with emphasis on receipt and impact of adjuvant therapy". J. Neurooncol. 129 (3): 557–565. doi:10.1007/s11060-016-2210-1. PMID 27401155.
- ↑ Wick W, Hartmann C, Engel C, Stoffels M, Felsberg J, Stockhammer F, Sabel MC, Koeppen S, Ketter R, Meyermann R, Rapp M, Meisner C, Kortmann RD, Pietsch T, Wiestler OD, Ernemann U, Bamberg M, Reifenberger G, von Deimling A, Weller M (December 2009). "NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide". J. Clin. Oncol. 27 (35): 5874–80. doi:10.1200/JCO.2009.23.6497. PMID 19901110.
- ↑ Wick W, Roth P, Hartmann C, Hau P, Nakamura M, Stockhammer F, Sabel MC, Wick A, Koeppen S, Ketter R, Vajkoczy P, Eyupoglu I, Kalff R, Pietsch T, Happold C, Galldiks N, Schmidt-Graf F, Bamberg M, Reifenberger G, Platten M, von Deimling A, Meisner C, Wiestler B, Weller M (November 2016). "Long-term analysis of the NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomide". Neuro-oncology. 18 (11): 1529–1537. doi:10.1093/neuonc/now133. PMC 5063521. PMID 27370396.
- ↑ Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO (March 2005). "Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma". N. Engl. J. Med. 352 (10): 987–96. doi:10.1056/NEJMoa043330. PMID 15758009.
- ↑ Kole AJ, Park HS, Yeboa DN, Rutter CE, Corso CD, Aneja S, Lester-Coll NH, Mancini BR, Knisely JP, Yu JB (August 2016). "Concurrent chemoradiotherapy versus radiotherapy alone for "biopsy-only" glioblastoma multiforme". Cancer. 122 (15): 2364–70. doi:10.1002/cncr.30063. PMID 27172136.
- ↑ Lai A, Tran A, Nghiemphu PL, Pope WB, Solis OE, Selch M, Filka E, Yong WH, Mischel PS, Liau LM, Phuphanich S, Black K, Peak S, Green RM, Spier CE, Kolevska T, Polikoff J, Fehrenbacher L, Elashoff R, Cloughesy T (January 2011). "Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme". J. Clin. Oncol. 29 (2): 142–8. doi:10.1200/JCO.2010.30.2729. PMC 3058273. PMID 21135282.
- ↑ Stupp R, Wong ET, Kanner AA, Steinberg D, Engelhard H, Heidecke V, Kirson ED, Taillibert S, Liebermann F, Dbalý V, Ram Z, Villano JL, Rainov N, Weinberg U, Schiff D, Kunschner L, Raizer J, Honnorat J, Sloan A, Malkin M, Landolfi JC, Payer F, Mehdorn M, Weil RJ, Pannullo SC, Westphal M, Smrcka M, Chin L, Kostron H, Hofer S, Bruce J, Cosgrove R, Paleologous N, Palti Y, Gutin PH (September 2012). "NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality". Eur. J. Cancer. 48 (14): 2192–202. doi:10.1016/j.ejca.2012.04.011. PMID 22608262.
- ↑ Westphal M, Hilt DC, Bortey E, Delavault P, Olivares R, Warnke PC, Whittle IR, Jääskeläinen J, Ram Z (April 2003). "A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma". Neuro-oncology. 5 (2): 79–88. doi:10.1093/neuonc/5.2.79. PMC 1920672. PMID 12672279.